WO2000026247A3 - Ikaros isoforms and mutants - Google Patents

Ikaros isoforms and mutants Download PDF

Info

Publication number
WO2000026247A3
WO2000026247A3 PCT/US1999/026274 US9926274W WO0026247A3 WO 2000026247 A3 WO2000026247 A3 WO 2000026247A3 US 9926274 W US9926274 W US 9926274W WO 0026247 A3 WO0026247 A3 WO 0026247A3
Authority
WO
WIPO (PCT)
Prior art keywords
ikaros
mutants
ikaros isoforms
isoforms
lymphoid cell
Prior art date
Application number
PCT/US1999/026274
Other languages
French (fr)
Other versions
WO2000026247A8 (en
WO2000026247A2 (en
WO2000026247A9 (en
Inventor
Fatih M Uckun
Mya L Crotty
Original Assignee
Parker Hughes Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parker Hughes Inst filed Critical Parker Hughes Inst
Priority to EP99961606A priority Critical patent/EP1127070A2/en
Priority to JP2000579634A priority patent/JP2002531066A/en
Priority to AU18148/00A priority patent/AU1814800A/en
Priority to CA002349417A priority patent/CA2349417A1/en
Publication of WO2000026247A2 publication Critical patent/WO2000026247A2/en
Publication of WO2000026247A3 publication Critical patent/WO2000026247A3/en
Publication of WO2000026247A9 publication Critical patent/WO2000026247A9/en
Publication of WO2000026247A8 publication Critical patent/WO2000026247A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Specific Ikaros mutations, as well as the correlation of the presence of the specific Ikaros mutations and other wild-type non-DNA binding Ikaros isoforms with lymphoid cell abnormality is provided in the invention. Methods for detecting and treating lymphoid cell abnormality, including hematologic malignancy, are also provided.
PCT/US1999/026274 1998-11-05 1999-11-05 Ikaros isoforms and mutants WO2000026247A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99961606A EP1127070A2 (en) 1998-11-05 1999-11-05 $i(IKAROS) ISOFORMS AND MUTANTS
JP2000579634A JP2002531066A (en) 1998-11-05 1999-11-05 IKAROS isoforms and mutants
AU18148/00A AU1814800A (en) 1998-11-05 1999-11-05 (Ikaros) isoforms and mutants
CA002349417A CA2349417A1 (en) 1998-11-05 1999-11-05 Ikaros isoforms and mutants

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10722998P 1998-11-05 1998-11-05
US15108799P 1999-08-27 1999-08-27
US60/151,087 1999-08-27
US60/107,229 1999-08-27

Publications (4)

Publication Number Publication Date
WO2000026247A2 WO2000026247A2 (en) 2000-05-11
WO2000026247A3 true WO2000026247A3 (en) 2000-11-16
WO2000026247A9 WO2000026247A9 (en) 2002-08-22
WO2000026247A8 WO2000026247A8 (en) 2003-11-06

Family

ID=26804552

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/026274 WO2000026247A2 (en) 1998-11-05 1999-11-05 Ikaros isoforms and mutants

Country Status (5)

Country Link
EP (1) EP1127070A2 (en)
JP (1) JP2002531066A (en)
AU (1) AU1814800A (en)
CA (1) CA2349417A1 (en)
WO (1) WO2000026247A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1960551A2 (en) * 2005-12-01 2008-08-27 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2009061890A1 (en) * 2007-11-08 2009-05-14 St. Jude Children's Research Hospital Methods and compositions for the diagnosis, prognosis and treatment of chronic myeloid leukemia and acute lymphoblastic leukemia
AU2011246976B2 (en) 2010-04-29 2016-01-28 Allarity Therapeutics Europe ApS Methods and devices for predicting treatment efficacy
EP2616556B1 (en) * 2010-09-13 2018-12-26 Clinical Genomics Pty Ltd Epigenetic markers of colorectal cancers and diagnostic methods using the same
DK3198035T3 (en) 2014-09-26 2023-01-30 Allarity Therapeutics Europe ApS Methods for predicting drug response
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
CN107034291A (en) * 2017-05-26 2017-08-11 首都医科大学附属北京儿童医院 The kit of children acute lymphoblastic leukaemia genotyping

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824770A (en) * 1992-09-14 1998-10-20 The General Hospital Corporation Ikaros polypeptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824770A (en) * 1992-09-14 1998-10-20 The General Hospital Corporation Ikaros polypeptides

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
F.M. UCKUN ET AL.: "IKAROS gene mutations and expression of dominant-negative IKAROS isoforms in childhood acute lymphoblastic leukemia", PAACRA, vol. 40, March 1999 (1999-03-01), pages 282, XP000914997 *
GEORGOPOULOS K ET AL: "THE ROLE OF THE IKAROS GENE IN LYMPHOCYTE DEVELOPMENT AND HOMEOSTASIS", ANNUAL REVIEW OF IMMUNOLOGY,US,ANNUAL REVIEWS INC, vol. 15, 1 January 1997 (1997-01-01), pages 155 - 176, XP000749983, ISSN: 0732-0582 *
H. NAKAYAMA ET AL.: "Aberrant IKAROS expression in human nonlymphoid leukemia cell-lines", BLOOD, vol. 88, no. 10, 15 November 1996 (1996-11-15), pages 3165, XP000864665 *
H. NAKAYAMA ET AL.: "Dominant-negative mutants of Ikaros gene in human lymphoid leukemia cell lines", BLOOD, vol. 90, 15 November 1997 (1997-11-15), pages 493A, XP000864669 *
HILLIER L ET AL.: "Human cDNA clone IMAGE:651072; IKAROS/LYF-1 homologue.", EMBL SEQUENCE DATABASE, 22 February 1997 (1997-02-22), HEIDELBERG DE, XP002141591 *
L. SUN ET AL.: "Expression of aberrantly spliced oncogenic Ikaros isoforms in childhood acute lymphoblastic leukemia", JOURNAL OF CLINICAL ONCOLOGY, vol. 17, December 1999 (1999-12-01), pages 3753 - 3766, XP000864666 *
L. SUN ET AL: "Gene mutations and expression of dominant-negative IKAROS isoforms in T-cell acute lymphoblastic leukemia", BLOOD, vol. 92, 15 November 1998 (1998-11-15), pages 152A, XP000864668 *
WINANDY S ET AL: "A DOMINANT MUTATION IN THE IKAROS GENE LEADS TO RAPID DEVELOPMENT OF LEUKEMIA AND LYMPHOMA", CELL,US,CELL PRESS, CAMBRIDGE, NA, vol. 83, 20 October 1995 (1995-10-20), pages 289 - 299, XP000749955, ISSN: 0092-8674 *

Also Published As

Publication number Publication date
CA2349417A1 (en) 2000-05-11
WO2000026247A8 (en) 2003-11-06
WO2000026247A2 (en) 2000-05-11
WO2000026247A9 (en) 2002-08-22
AU1814800A (en) 2000-05-22
EP1127070A2 (en) 2001-08-29
JP2002531066A (en) 2002-09-24

Similar Documents

Publication Publication Date Title
AU2597397A (en) Methods of recovering colorectal epithelial cells or fragments thereof from stool
HUP0100025A3 (en) Methods for treating hypercoagulable states or acquired protein c deficiency
NO982126D0 (en) Polymer burn compartment compositions and auxiliary compositions and methods for their use
WO1997036535A3 (en) Biomarkers for detection, diagnosis and prognosis of prostate cancer
WO2002006529A3 (en) Detection and treatment of polycystic kidney disease
WO2001004264A3 (en) Atherosclerosis-associated genes
EP1061806A4 (en) Producer cells for replication selective viruses in the treatment of malignancy
WO2003018758A3 (en) Reagents and methods for smooth muscle therapies
EP0985150A4 (en) Method for detecting cancer associated with altered concentrations of lysophospholipids
WO2000026247A3 (en) Ikaros isoforms and mutants
DK0760010T3 (en) Methods for screening for Crohn's disease using TNF microsatellite alleles
AU3399295A (en) Method of detecting autoantibody present in the serum of reumatic
AU1855401A (en) Screening method for candidate drugs
WO2001009384A3 (en) Serial analysis of genetic alterations
AU3444899A (en) Method for the rapid determination of bacteria
ZA976642B (en) Methods for sludge dewatering.
AU3028497A (en) Use of triazine-based uvas for use as quenchers in paper-making processes
AU3140497A (en) Methods and kits for the detection of endotoxin
ZA972247B (en) Combination of enzymes for the destruction of proliferative cells.
AU4480997A (en) Screening methods for compounds useful in the treatment of schizophrenia
AU6695894A (en) Lysimeter for collecting chemical samples from the vadose zone
WO2000066769A3 (en) System and method for screening of nasopharyngeal carcinoma
PL344785A1 (en) Methods for increasing levels of acetylcholine
AU4248097A (en) Methods for processing chemical compounds having reactive functional groups
WO2000021996A3 (en) Methods and compositions for inhibiting neoplastic cell growth

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 18148

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 18148/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2349417

Country of ref document: CA

Ref country code: JP

Ref document number: 2000 579634

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: CA

Ref document number: 2349417

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999961606

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999961606

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999961606

Country of ref document: EP

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/13-13/13, DRAWINGS, REPLACED BY NEW PAGES 1/26-26/26; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 19/2000 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION.

Free format text: IN PCT GAZETTE 19/2000 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION.